Proliferative diabetic retinopathy: Role of bevacizumab in decreasing the occurrence of vitreous hemorrhage after panretinal photocoagulation

To investigate the beneficial effect of bevacizumab injection one week prior to panretinal photocoagulation (PRP) on the occurrence of vitreous hemorrhage (VH) following PRP in high-risk proliferative diabetic retinopathy (PDR). This was a case-control pilot study conducted on two groups: an anti-VE...

Full description

Saved in:
Bibliographic Details
Published inJournal francais d'ophtalmologie Vol. 47; no. 1; p. 103946
Main Authors Nehme, J, Karam, M Abi, Haber, C, Hanna, N G, Farhat, R, Sahyoun, M, Schakal, A, Samaha, A, Azar, G, Jalkh, A
Format Journal Article
LanguageEnglish
Published France 01.01.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract To investigate the beneficial effect of bevacizumab injection one week prior to panretinal photocoagulation (PRP) on the occurrence of vitreous hemorrhage (VH) following PRP in high-risk proliferative diabetic retinopathy (PDR). This was a case-control pilot study conducted on two groups: an anti-VEGF treatment group, treated with bevacizumab injection one week prior to the first PRP session, and a control group of treatment-naive PDR patients who underwent PRP treatment and were not given an intravitreal bevacizumab injection, consecutively recruited. In both groups, a complete ophthalmological examination was conducted prior to PRP and at 4, 9, and 16 weeks following treatment. The primary endpoint studied was the occurrence of VH. The control group included 69 patients (mean age 63±12.3 years) with high-risk PDR who received PRP treatment only, and the anti-VEGF treatment group included 67 patients (mean age 63.13±10.3 years). None of the demographic variables or comorbidities showed any significant difference between the two groups. The number of PRP sessions was not significantly correlated to the occurrence of VH in either of the groups (P=0.167). Vitreous hemorrhage within 16 weeks following laser treatment occurred in 10 patients (14.5%) in the control group and in only 3 patients (4.5%) in the anti-VEGF group (P=0.047). Our case-control pilot study demonstrates that a bevacizumab injection preceding the initial PRP session might be beneficial in reducing the occurrence of VH in the first 16 weeks following PRP.
AbstractList To investigate the beneficial effect of bevacizumab injection one week prior to panretinal photocoagulation (PRP) on the occurrence of vitreous hemorrhage (VH) following PRP in high-risk proliferative diabetic retinopathy (PDR). This was a case-control pilot study conducted on two groups: an anti-VEGF treatment group, treated with bevacizumab injection one week prior to the first PRP session, and a control group of treatment-naive PDR patients who underwent PRP treatment and were not given an intravitreal bevacizumab injection, consecutively recruited. In both groups, a complete ophthalmological examination was conducted prior to PRP and at 4, 9, and 16 weeks following treatment. The primary endpoint studied was the occurrence of VH. The control group included 69 patients (mean age 63±12.3 years) with high-risk PDR who received PRP treatment only, and the anti-VEGF treatment group included 67 patients (mean age 63.13±10.3 years). None of the demographic variables or comorbidities showed any significant difference between the two groups. The number of PRP sessions was not significantly correlated to the occurrence of VH in either of the groups (P=0.167). Vitreous hemorrhage within 16 weeks following laser treatment occurred in 10 patients (14.5%) in the control group and in only 3 patients (4.5%) in the anti-VEGF group (P=0.047). Our case-control pilot study demonstrates that a bevacizumab injection preceding the initial PRP session might be beneficial in reducing the occurrence of VH in the first 16 weeks following PRP.
ArticleNumber 103946
Author Karam, M Abi
Haber, C
Azar, G
Sahyoun, M
Samaha, A
Farhat, R
Jalkh, A
Nehme, J
Schakal, A
Hanna, N G
Author_xml – sequence: 1
  givenname: J
  surname: Nehme
  fullname: Nehme, J
  email: nehmejoseph@hotmail.com
  organization: Faculty of Medicine, Holy Spirit University, Kaslik, Jounieh, Lebanon; Eye and Ear University Hospital, Naccash Road, Dbayeh, Metn, Lebanon. Electronic address: nehmejoseph@hotmail.com
– sequence: 2
  givenname: M Abi
  surname: Karam
  fullname: Karam, M Abi
  organization: Faculty of Medicine, Holy Spirit University, Kaslik, Jounieh, Lebanon; Eye and Ear University Hospital, Naccash Road, Dbayeh, Metn, Lebanon
– sequence: 3
  givenname: C
  surname: Haber
  fullname: Haber, C
  organization: Faculty of Medicine, Holy Spirit University, Kaslik, Jounieh, Lebanon
– sequence: 4
  givenname: N G
  surname: Hanna
  fullname: Hanna, N G
  organization: Faculty of Medicine, Holy Spirit University, Kaslik, Jounieh, Lebanon; Eye and Ear University Hospital, Naccash Road, Dbayeh, Metn, Lebanon
– sequence: 5
  givenname: R
  surname: Farhat
  fullname: Farhat, R
  organization: Faculty of Medicine, Holy Spirit University, Kaslik, Jounieh, Lebanon; Eye and Ear University Hospital, Naccash Road, Dbayeh, Metn, Lebanon
– sequence: 6
  givenname: M
  surname: Sahyoun
  fullname: Sahyoun, M
  organization: Faculty of Medicine, Holy Spirit University, Kaslik, Jounieh, Lebanon; Eye and Ear University Hospital, Naccash Road, Dbayeh, Metn, Lebanon
– sequence: 7
  givenname: A
  surname: Schakal
  fullname: Schakal, A
  organization: Faculty of Medicine, Holy Spirit University, Kaslik, Jounieh, Lebanon; Eye and Ear University Hospital, Naccash Road, Dbayeh, Metn, Lebanon
– sequence: 8
  givenname: A
  surname: Samaha
  fullname: Samaha, A
  organization: Faculty of Medicine, Holy Spirit University, Kaslik, Jounieh, Lebanon; Eye and Ear University Hospital, Naccash Road, Dbayeh, Metn, Lebanon
– sequence: 9
  givenname: G
  surname: Azar
  fullname: Azar, G
  organization: Faculty of Medicine, Holy Spirit University, Kaslik, Jounieh, Lebanon; Eye and Ear University Hospital, Naccash Road, Dbayeh, Metn, Lebanon
– sequence: 10
  givenname: A
  surname: Jalkh
  fullname: Jalkh, A
  organization: Faculty of Medicine, Holy Spirit University, Kaslik, Jounieh, Lebanon; Eye and Ear University Hospital, Naccash Road, Dbayeh, Metn, Lebanon
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37833204$$D View this record in MEDLINE/PubMed
BookMark eNo9kN9KwzAUh4NM3NQ9gDeSF2g9adom806G_2CgiF6XJD1ZM7qmpO1gvoPvbN3Um3Pg8Pt-B75zMml8g4RcMYgZsPxmE2-sjxNIeAwyBkhPyIwJwSPIFmJCZsAki7KMJVMy7zqngS3yRIyHMzLlQnKeQDojX6_B185iUL3bIS2d0tg7Q8M4G9-qvtrf0jdfI_WWatwp4z6HrdLUNbREE1B1rlnTvhoDxgwhYGMO2Z3rA_qhoxVufQiVWiNVtsdAW9Uc2lVN28r33ni1Hurxv28uyalVdYfz331BPh7u35dP0erl8Xl5t4oMh6yPcjAopRQpx9JyabWGMkcGqRAKbCKsYQBa22xRpphzxaWRSYYMlUULYsEvCDv2muC7LqAt2uC2KuwLBsWP3WJTjHaLH7sFyGK0OzLXR6Yd9BbLf-LPJf8GUBp9QQ
Cites_doi 10.1097/00004397-198702740-00004
10.1016/j.ophtha.2011.01.031
10.1016/S0161-6420(91)32085-2
10.1016/0002-9394(76)90292-0
10.1016/S1350-9462(02)00043-5
10.1016/j.ophtha.2010.02.031
10.1097/00006982-200603000-00016
10.1111/j.1442-9071.2006.01378.x
10.1016/S0161-6420(13)38009-9
10.1016/S0161-6420(85)34016-2
10.1097/IAE.0b013e31818356fb
10.1001/jama.2015.15217
10.1001/archopht.1994.01090230090028
10.1001/jama.2010.1111
10.1111/j.1600-0420.2007.01056.x
10.1097/IAE.0000000000001673
10.2337/diacare.27.10.2540
10.2337/diab.35.4.416
ContentType Journal Article
Copyright Copyright © 2023 Elsevier Masson SAS. All rights reserved.
Copyright_xml – notice: Copyright © 2023 Elsevier Masson SAS. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
DOI 10.1016/j.jfo.2023.08.004
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1773-0597
ExternalDocumentID 10_1016_j_jfo_2023_08_004
37833204
Genre Journal Article
GroupedDBID ABJNI
ALMA_UNASSIGNED_HOLDINGS
CGR
CUY
CVF
ECM
EIF
NPM
08J
08T
0R~
4.4
457
53G
AAEDT
AALRI
AAXUO
AAYXX
AFJKZ
AFNOS
AFTJW
AITUG
AMRAJ
AOOFG
CITATION
DIK
EBS
EJD
FDB
HZ~
O9-
SEM
SES
ID FETCH-LOGICAL-c305t-60ce888743edf38fbb0d6e10477a0f27fc100bbf59d4e63a38c825e1eafef0793
ISSN 0181-5512
IngestDate Thu Sep 26 17:52:34 EDT 2024
Thu Oct 24 09:27:21 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Bévacizumab
Proliferative diabetic retinopathy
Vitreous hemorrhage
Panretinal photocoagulation
Hémorragie vitréenne
Photocoagulation panrétinienne
Rétinopathie diabétique proliférative
Bevacizumab
Language English
License Copyright © 2023 Elsevier Masson SAS. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c305t-60ce888743edf38fbb0d6e10477a0f27fc100bbf59d4e63a38c825e1eafef0793
PMID 37833204
ParticipantIDs crossref_primary_10_1016_j_jfo_2023_08_004
pubmed_primary_37833204
PublicationCentury 2000
PublicationDate 2024-Jan
2024-01-00
PublicationDateYYYYMMDD 2024-01-01
PublicationDate_xml – month: 01
  year: 2024
  text: 2024-Jan
PublicationDecade 2020
PublicationPlace France
PublicationPlace_xml – name: France
PublicationTitle Journal francais d'ophtalmologie
PublicationTitleAlternate J Fr Ophtalmol
PublicationYear 2024
References Malecaze (10.1016/j.jfo.2023.08.004_bib0140) 1994; 112
Vander (10.1016/j.jfo.2023.08.004_bib0185) 1991; 98
(10.1016/j.jfo.2023.08.004_bib0215) 1991; 98
Grant (10.1016/j.jfo.2023.08.004_bib0135) 1986; 35
Avery (10.1016/j.jfo.2023.08.004_bib0195) 2006; 26
(10.1016/j.jfo.2023.08.004_bib0145) 1987; 27
Zhang (10.1016/j.jfo.2023.08.004_bib0115) 2010; 304
McDonald (10.1016/j.jfo.2023.08.004_bib0150) 1985; 92
Elman (10.1016/j.jfo.2023.08.004_bib0155) 2010; 117
Frank (10.1016/j.jfo.2023.08.004_bib0220) 2005; 46
Tonello (10.1016/j.jfo.2023.08.004_bib0190) 2008; 86
Avery (10.1016/j.jfo.2023.08.004_bib0165) 2006; 26
Fong (10.1016/j.jfo.2023.08.004_bib0125) 2004; 27
Gross (10.1016/j.jfo.2023.08.004_bib0210) 2015; 314
Witmer (10.1016/j.jfo.2023.08.004_bib0130) 2003; 22
Mitchell (10.1016/j.jfo.2023.08.004_bib0160) 2011; 118
Chelala (10.1016/j.jfo.2023.08.004_bib0205) 2018; 38
Isaacs (10.1016/j.jfo.2023.08.004_bib0170) 2006; 34
Akduman (10.1016/j.jfo.2023.08.004_bib0175) 1998
(10.1016/j.jfo.2023.08.004_bib0120) 1976; 81
Mason (10.1016/j.jfo.2023.08.004_bib0200) 2008; 28
References_xml – volume: 27
  start-page: 239
  year: 1987
  ident: 10.1016/j.jfo.2023.08.004_bib0145
  article-title: Indications for photocoagulation treatment of diabetic retinopathy: diabetic retinopathy study report No. 14
  publication-title: Int Ophthalmol Clin
  doi: 10.1097/00004397-198702740-00004
– volume: 118
  start-page: 615
  year: 2011
  ident: 10.1016/j.jfo.2023.08.004_bib0160
  article-title: The RESTORE study. Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2011.01.031
  contributor:
    fullname: Mitchell
– volume: 98
  start-page: 1575
  year: 1991
  ident: 10.1016/j.jfo.2023.08.004_bib0185
  article-title: Long-term stability and visual outcome after favourable initial response of proliferative diabetic retinopathy to panretinal photocoagulation
  publication-title: Ophthalmology
  doi: 10.1016/S0161-6420(91)32085-2
  contributor:
    fullname: Vander
– volume: 81
  start-page: 383
  year: 1976
  ident: 10.1016/j.jfo.2023.08.004_bib0120
  article-title: Preliminary report on effects of photocoagulation therapy
  publication-title: Am J Ophthalmol
  doi: 10.1016/0002-9394(76)90292-0
– volume: 22
  start-page: 1
  year: 2003
  ident: 10.1016/j.jfo.2023.08.004_bib0130
  article-title: Vascular endothelial growth factors and angiogenesis in eye disease
  publication-title: Prog Retin Eye Res
  doi: 10.1016/S1350-9462(02)00043-5
  contributor:
    fullname: Witmer
– volume: 117
  start-page: 1064
  year: 2010
  ident: 10.1016/j.jfo.2023.08.004_bib0155
  article-title: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2010.02.031
  contributor:
    fullname: Elman
– volume: 26
  start-page: 352
  year: 2006
  ident: 10.1016/j.jfo.2023.08.004_bib0195
  article-title: Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment
  publication-title: Retina
  doi: 10.1097/00006982-200603000-00016
  contributor:
    fullname: Avery
– volume: 34
  start-page: 802
  year: 2006
  ident: 10.1016/j.jfo.2023.08.004_bib0170
  article-title: Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin)
  publication-title: Clin Experiment Ophthalmol
  doi: 10.1111/j.1442-9071.2006.01378.x
  contributor:
    fullname: Isaacs
– volume: 98
  start-page: 741
  year: 1991
  ident: 10.1016/j.jfo.2023.08.004_bib0215
  article-title: Early treatment diabetic retinopathy study design and baseline patient characteristics: ETDRS report number 7
  publication-title: Ophthalmology
  doi: 10.1016/S0161-6420(13)38009-9
– volume: 92
  start-page: 388
  year: 1985
  ident: 10.1016/j.jfo.2023.08.004_bib0150
  article-title: Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy
  publication-title: Ophthalmology
  doi: 10.1016/S0161-6420(85)34016-2
  contributor:
    fullname: McDonald
– start-page: 15
  year: 1998
  ident: 10.1016/j.jfo.2023.08.004_bib0175
  article-title: The early treatment for diabetic retinopathy study
  contributor:
    fullname: Akduman
– volume: 28
  start-page: 1319
  year: 2008
  ident: 10.1016/j.jfo.2023.08.004_bib0200
  article-title: Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy
  publication-title: Retina
  doi: 10.1097/IAE.0b013e31818356fb
  contributor:
    fullname: Mason
– volume: 314
  start-page: 2137
  year: 2015
  ident: 10.1016/j.jfo.2023.08.004_bib0210
  article-title: Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial
  publication-title: JAMA
  doi: 10.1001/jama.2015.15217
  contributor:
    fullname: Gross
– volume: 26
  start-page: 352
  year: 2006
  ident: 10.1016/j.jfo.2023.08.004_bib0165
  article-title: Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment
  publication-title: Retina
  doi: 10.1097/00006982-200603000-00016
  contributor:
    fullname: Avery
– volume: 112
  start-page: 1476
  year: 1994
  ident: 10.1016/j.jfo.2023.08.004_bib0140
  article-title: Detection of VEGF mRNA and VEGF like activity in proliferative diabetic retinopathy
  publication-title: Arch Ophthalmol
  doi: 10.1001/archopht.1994.01090230090028
  contributor:
    fullname: Malecaze
– volume: 304
  start-page: 649
  year: 2010
  ident: 10.1016/j.jfo.2023.08.004_bib0115
  article-title: Prevalence of diabetic retinopathy in the United States, 2005–2008
  publication-title: JAMA
  doi: 10.1001/jama.2010.1111
  contributor:
    fullname: Zhang
– volume: 86
  start-page: 385
  year: 2008
  ident: 10.1016/j.jfo.2023.08.004_bib0190
  article-title: Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study)
  publication-title: Acta Ophthalmol
  doi: 10.1111/j.1600-0420.2007.01056.x
  contributor:
    fullname: Tonello
– volume: 38
  start-page: 1127
  year: 2018
  ident: 10.1016/j.jfo.2023.08.004_bib0205
  article-title: Efficacy of intravitreal ranibizumab injections in the treatment of vitreous hemorrhage related to proliferative diabetic retinopathy
  publication-title: Retina
  doi: 10.1097/IAE.0000000000001673
  contributor:
    fullname: Chelala
– volume: 46
  start-page: 4794
  year: 2005
  ident: 10.1016/j.jfo.2023.08.004_bib0220
  article-title: Anticoagulant drugs do not increase the risk of vitreous hemorrhage in proliferative diabetic retinopathy or retinal vein occlusions
  publication-title: Invest Ophthalmol Vis Sci
  contributor:
    fullname: Frank
– volume: 27
  start-page: 2540
  year: 2004
  ident: 10.1016/j.jfo.2023.08.004_bib0125
  article-title: Diabetic retinopathy
  publication-title: Diabetes Care
  doi: 10.2337/diacare.27.10.2540
  contributor:
    fullname: Fong
– volume: 35
  start-page: 416
  year: 1986
  ident: 10.1016/j.jfo.2023.08.004_bib0135
  article-title: Insulin-like growth factor in vitreous. Studies in control and diabetic subjects with neovascularization
  publication-title: Diabetes
  doi: 10.2337/diab.35.4.416
  contributor:
    fullname: Grant
SSID ssib019627551
ssib053390985
ssj0003755
Score 2.3525693
Snippet To investigate the beneficial effect of bevacizumab injection one week prior to panretinal photocoagulation (PRP) on the occurrence of vitreous hemorrhage (VH)...
SourceID crossref
pubmed
SourceType Aggregation Database
Index Database
StartPage 103946
SubjectTerms Aged
Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized - adverse effects
Bevacizumab - adverse effects
Diabetes Mellitus - drug therapy
Diabetic Retinopathy - drug therapy
Diabetic Retinopathy - epidemiology
Humans
Intravitreal Injections
Laser Coagulation - adverse effects
Middle Aged
Pilot Projects
Vitreous Hemorrhage - epidemiology
Vitreous Hemorrhage - etiology
Vitreous Hemorrhage - therapy
Title Proliferative diabetic retinopathy: Role of bevacizumab in decreasing the occurrence of vitreous hemorrhage after panretinal photocoagulation
URI https://www.ncbi.nlm.nih.gov/pubmed/37833204
Volume 47
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LaxsxEBYmhdJL6btJH-jQU8Mu8mpf7i2UtmmKTSgJ5LZIstRdQ3aNs84h_6H_oj-0M9I-3RSaXsQihLA1HzOj0cw3hLxjUSAEgMWbcpN6oeDcE7EIPKbZMom0SaUNXcwX8fF5eHIRXUwmvwZZS9ta-urm1rqS_5EqzIFcsUr2DpLtNoUJ-Ab5wggShvGfZHyKLXeMbsi7XRjVUjLXRVlhr2FL5_S9SSCU-lqo4mZ7KaTLgUWH8aotl6qUslRNyq69LuqNxuzYHDNxNzlm9rh24mskCKptL611XtWVqsSPpgXYbY6uAVtoH-MTUVwdwgEl1ToHh__SKt0OVQudu3btJ35nAsTGgXXuHx7JoleVsqld9Pup0lW2Lfwv_jCMEYSDMEYT2UynHrhvI9XsyDhHEHR6Fh-wXejyDxPgohErf2WwtjPglqHVtTge023vmMEuObHNe1tlsEWGW2TYqRNJZ-8FyMePrvfXb52950nkEmWbP9C-ndsswp1fMfJ-RvcY68-cPSIPG_nQI4eqx2Siyyfk_rxJtXhKfo7ARVtw0QG4PlCEFq0MHUCLFiXtoUUBWrSHFq5toUV7aFELLdpDi-5C6xk5__zp7OOx1_Tu8BRYkNqLmdIpGLCQ66XhqZGSLWONvCCJYCZIjJoyJqWJZstQx1zwVKVBpKdaGG2QtPE52SurUr8kVEShScCPUnAXgetDIvmMcS5mUhuRggraJ-_bM83WjqIl-6sM98kLd-rdUp6knAcsPLjLNq_Igx7Er8levdnqN-Cd1vKtBQeMi9P5bzY-lQ8
link.rule.ids 315,786,790,27946,27947
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Proliferative+diabetic+retinopathy%3A+Role+of+bevacizumab+in+decreasing+the+occurrence+of+vitreous+hemorrhage+after+panretinal+photocoagulation&rft.jtitle=Journal+fran%C3%A7ais+d%27ophtalmologie&rft.au=Nehme%2C+J.&rft.au=Karam%2C+M.+Abi&rft.au=Haber%2C+C.&rft.au=Hanna%2C+N.G.&rft.date=2024-01-01&rft.issn=0181-5512&rft.volume=47&rft.issue=1&rft.spage=103946&rft_id=info:doi/10.1016%2Fj.jfo.2023.08.004&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_jfo_2023_08_004
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0181-5512&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0181-5512&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0181-5512&client=summon